Search
Synlogic Inc
SYBXAdd to Watchlist
0.560USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.20MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-52.14%
Year to Date
-50.00%
1 Year
-52.54%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
30.54%Turnover Ratio
0.560Prev. Close
0.000Low
0.00Turnover
LossP/E Static
0.63P/B
0.00%Div Yield TTM
-17.30%ROA
1.96052wk High
415.55Volume Ratio
-23.36MNet Profit
11.70MShares
-0.2613EPS TTM
0.55Beta
-27.54%ROE
0.89852wk Low
19.36%Amplitude
100.00%Gross Margin
8.20MMarket Cap
-0.22Reward/Risk
3.95%Risk Rate
TradingKey Stock Score of Synlogic Inc
Currency: USD Updated: 2026-01-20Key Insights
Synlogic Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 223 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 1.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Synlogic Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Synlogic Inc Highlights
StrengthsRisks
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.00K.
Undervalued
The company’s latest PE is -2.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 7.45M shares, decreasing 3.08% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 196.46K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
1.000
Target Price
-16.67%
Upside Space
Synlogic Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Synlogic Inc Info
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Ticker SymbolSYBX
CompanySynlogic Inc
CEO
Websitehttps://www.synlogictx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Synlogic Inc (SYBX)?
The current price of Synlogic Inc (SYBX) is 0.56.
What is the symbol of Synlogic Inc?
The ticker symbol of Synlogic Inc is SYBX.
What is the 52-week high of Synlogic Inc?
The 52-week high of Synlogic Inc is 1.96.
What is the 52-week low of Synlogic Inc?
The 52-week low of Synlogic Inc is 0.90.
What is the market capitalization of Synlogic Inc?
The market capitalization of Synlogic Inc is 8.20M.
What is the Earnings Per Share (EPS TTM) of Synlogic Inc (SYBX)?
The Earnings Per Share (EPS TTM) of Synlogic Inc (SYBX) is -0.08.